Silencing DACH1 promotes esophageal cancer growth by inhibiting tgf-b signaling

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Wu, Liang ^a   Herman, James G ^b   Brock, Malcolm V ^b   Wu, Kongming ^c   Mao, Gaoping ^d   Yan, Wenji ^a   Nie, Yan ^e   Liang, Hao ^a   Zhan, Qimin ^f   Li, Wen ^a   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d AIR FORCE GENERAL HOSPITAL   (China)

^e Department of Gastroenterology and Hepatology Affiliated Hainan Hospital of the Chinese PLA General Hospital   (China)

^f CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; DACH1 PROTEIN, HUMAN; EYE PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CARCINOGENICITY; COLONY FORMATION; CONTROLLED STUDY; CYTOMETRY; DYSPLASIA; ENZYME ACTIVATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN DACHSHUND HOMOLOGUE 1 GENE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL SURVIVAL; DNA METHYLATION; ESOPHAGUS TUMOR; FLOW CYTOMETRY; GENETIC EPIGENESIS; GENETICS; METABOLISM; PHYSIOLOGY;

ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; EYE PROTEINS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84899673791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095509     Document Type: Article

References (36)

1. Chen W, Zheng R, Zhang S, Zhao P, Li G, et al. (2013) The incidences and mortalities of major cancers in China, 2009. Chin J Cancer 32: 106-112.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
3. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
4. Kuwano H, Kato H, Miyazaki T, Fukuchi M, Masuda N, et al. (2005) Genetic alterations in esophageal cancer. Surgery today 35: 7-18.
5. Sato F, Meltzer SJ (2006) CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 106: 483-493.
6. Talukdar FR, Ghosh SK, Laskar RS, Mondal R (2013) Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from northeast India. PloS one 8: e60996.
7. Chen K, Wu K, Gormley M, Ertel A, Wang J, et al. (2013) Acetylation of the Cell-Fate Factor Dachshund Determines p53 Binding and Signaling Modules in Breast Cancer. Oncotarget 4: 923-935.
8. Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, et al. (2009) The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res 69: 3347-3355.
9. Chen K, Wu K, Cai S, Zhang W, Zhou J, et al. (2013) Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer research 73: 3262-3274.
10. Nan F, Lu Q, Zhou J, Cheng L, Popov VM, et al. (2009) Altered expression of DACH1 and cyclin D1 in endometrial cancer. Cancer Biol Ther 8: 1534-1539.
11. Deng XC, Li SR, Zhang Q, Zhou CJ, Yang QF, et al. (2012) [Analysis of the status of DACH1 gene promoter methylation in endometrial carcinoma and its clinical significance]. Zhonghua fu chan ke za zhi 47: 263-267.
12. Yan W, Wu K, Herman JG, Brock MV, Fuks F, et al. (2013) Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics 8.
13. Zhu H, Wu K, Yan W, Hu L, Yuan J, et al. (2013) Epigenetic silencing of DACH1 induces loss of transforming growth factor-beta1 antiproliferative response in human hepatocellular carcinoma. Hepatology 58: 2012-2022.
14. Guo M, Liu S, Herman JG, Zhuang H, Lu F (2006) Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther 5: 152-155.
15. Jia Y, Yang Y, Brock MV, Cao B, Zhan Q, et al. (2012) Methylation of TFPI-2 is an early event of esophageal carcinogenesis. Epigenomics 4: 135-146.
16. Jia Y, Yang Y, Zhan Q, Brock MV, Zheng X, et al. (2012) Inhibition of SOX17 by microRNA 141 and methylation activates the WNT signaling pathway in esophageal cancer. J Mol Diagn 14: 577-585.
17. Guo M, House MG, Suzuki H, Ye Y, Brock MV, et al. (2007) Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer 121: 1219-1226.
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America 93: 9821-9826.
19. Jia Y, Yang Y, Liu S, Herman JG, Lu F, et al. (2010) SOX17 antagonizes WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Epigenetics : official journal of the DNA Methylation Society 5: 743-749.
20. Wu K, Yang Y, Wang C, Davoli MA, D'Amico M, et al. (2003) DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem 278: 51673-51684.
21. Liang F, Lu Q, Sun S, Zhou J, Popov VM, et al. (2012) Increased expression of dachshund homolog 1 in ovarian cancer as a predictor for poor outcome. Int J Gynecol Cancer 22: 386-393.
22. Guo M, Ren J, House MG, Qi Y, Brock MV, et al. (2006) Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 12: 4515-4522.
23. Guo M, Ren J, Brock MV, Herman JG, Carraway HE (2008) Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics 3: 336-341.
24. Massague J (2008) TGFbeta in Cancer. Cell 134: 215-230.
25. Ikushima H, Miyazono K (2010) TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10: 415-424.
26. Heldin CH, Landstrom M, Moustakas A (2009) Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 21: 166-176.
27. Bertolino P, Deckers M, Lebrin F, ten Dijke P (2005) Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest 128: 585S-590S.
28. Pardali K, Kowanetz M, Heldin CH, Moustakas A (2005) Smad pathwayspecific transcriptional regulation of the cell cycle inhibitor p21(WAF1/Cip1). J Cell Physiol 204: 260-272.
29. Chen CR, Kang Y, Siegel PM, Massague J (2002) E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110: 19-32.
30. Seoane J (2006) Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 27: 2148-2156.
31. Meulmeester E, Ten Dijke P (2011) The dynamic roles of TGF-beta in cancer. J Pathol 223: 205-218.
32. Inman GJ (2011) Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev 21: 93-99.
33. Tian M, Schiemann WP (2009) The TGF-beta paradox in human cancer: an update. Future Oncol 5: 259-271.
34. Zu X, Zhang Q, Cao R, Liu J, Zhong J, et al. (2012) Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell Tissue Res 347: 73-84.
35. Wu K, Li A, Rao M, Liu M, Dailey V, et al. (2006) DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol 26: 7116-7129.
36. Elston R, Inman GJ (2012) Crosstalk between p53 and TGF-beta Signalling. J Signal Transduct 2012: 294097.